VBL Therapeutics

146 articles with VBL Therapeutics

• VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLCAgreement extends current cash runway to Q1 2023

  1/15/2021

  VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, today announced that it has entered into an Ordinary Share Purchase Agreement with Aspire Capital Fund, LLC. Proceeds from any sales of ordinary shares pursuant to the Purchase Agreement will be used for workin

• 

  Clinical Catch-Up: December 28, 2020-January 1, 2021

  1/4/2021

  It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.

• VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

  12/29/2020

  Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe 

• VBL Therapeutics Announces Insider Buying

  12/7/2020

  VBL Therapeutics announced that the Company's Chairman of the Board, Dr. Bennett Shapiro, the CEO, Prof. Dror Harats and additional Company board members and senior management, made open-market purchases of approximately 200K shares of VBLT, between November 24 and December 3, 2020.

• VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/16/2020

  Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with approximately 200 patients enrolled to date

• VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference

  11/5/2020

  VBL Therapeutics announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Swayampakula Ramakanth, Ph.D., at the H.C. Wainwright 6th Annual Israel Conference to be held virtually on November 12th, 2020.

• VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16

  11/2/2020

  VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer

  10/15/2020

  VBL Therapeutics, announced that the European Patent Office has granted Patent #3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions.

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors

  10/13/2020

  VBL Therapeutics announced that it has appointed Marc Kozin as Vice Chairman of the Board.

• Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036

  10/12/2020

  VBL Therapeutics, announced that the European Patent Office has granted Patent #3328408, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions.

• VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference

  9/29/2020

  VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Geulah Livshits, PhD, at the Chardan 4th Annual Genetic Medicines Conference

• VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/21/2020

  VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020. Presentation Details: Date: Wednesda

• VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference

  9/15/2020

  - VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.   " Our OVAL trial of VB-111 in ovarian cancer continues to progress well, with over a third of the study participants already enrolled, " said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics.

• VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting

  9/11/2020

  VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting . Data show that VBL's anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolate

• VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer

  9/10/2020

  VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.

• 

  BioSpace Global Roundup, Sept. 10

  9/10/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601

  9/8/2020

  VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for VB-601.

• VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

  8/13/2020

  VBL Therapeutics announced financial results for the second quarter ended June 30, 2020, and provided a corporate update.